The Graying of the HIV/AIDS Epidemic in the U.S.

Slides:



Advertisements
Similar presentations
Scaling up HIV services for women and children achievements and challenges e-lluminate session e-lluminate session Yves Souteyrand 2 March 2010.
Advertisements

Metabolic consequences of HIV-induced inflammation Jacqueline Capeau INSERM U938, Université Pierre et Marie Curie Faculté de Médecine, site Saint-Antoine,
Key1 World Bank Training Program on HIV/AIDS Drugs Training Module 3 Selection and Quantification based on the World Bank document Battling HIV/AIDS: A.
HIV and STI Department, Health Protection Agency - Colindale HIV and AIDS Reporting System HIV in the UK – 30 years on… Since 1981: 122,000 HIV diagnoses.
Chronic Disease and Co-morbidity with Hearing Loss
No one left behind: Increased coverage, better programmes and maximum impact for key populations WHO Consolidated Guidelines on HIV Prevention, Diagnosis,
Aging, Inflammation, and Organ Damage in HIV+ Patients Jean-Pierre Routy, MD Graeme Moyle, MD Bill Powderly, MD Philippe Morlat, MD.
Laura Armas-Kolostroubis, MD University of Florida-Jacksonville Aging Issues Among Women Living with HIV.
ARV Nurse Training Programme Marcus McGilvray & Nicola Willis
HCV cure: new treatment paradigms for HCV infection Sanjay Bhagani Consultant Physician/Senior Lecturer Royal Free Hospital/UCL London.
HIV treatment as prevention Stephen Kegg. 2 Learning Outcomes Overview of HIV management HIV transmission risks Current prevention strategies Which new.
Towards an AIDS-Free Generation Women & Girls and HIV in PEPFAR
Evaluation of HIV status and its spread in HIV patients on RRT and their spouses Dr. Aditya Agarwal Clinical Fellow Indraprastha Apollo Hospitals, New.
HIV in the United Kingdom: 2013 HIV and AIDS Reporting Section Centre for Infectious Disease Surveillance and Control (CIDSC) Public Health England London,
The hidden HIV epidemic: what do mathematical models tell us? The case of France Virginie Supervie, Jacques Ndawinz & Dominique Costagliola U943 Inserm.
Maurice Cook ( EM Designs Group, Inc.) The End of AIDS Transmission? Robert M Grant, June 2012.
HIV in Texas: The Ways Forward Ann Robbins Manager of HIV/STD Prevention and Care Department of State Health Services.
Potential role of PEP, PrEP and ART for HIV Prevention among Men who have Sex with Men Frits van Griensven, PhD, MPH Division of HIV/AIDS Prevention US.
Chronic diseases in HIV Francois Venter Wits Reproductive Health & HIV Institute
I. Jean Davis, PhD, PA, AAHIVS Howard University College of Medicine.
Immunosenescence - Results of BELFRAIL (and INCIVAR) By Adriaensen Wim Department of Public Health and Primary Care, KU Leuven & UCL, Belgium.
HIV Disease in Older Patients Donna M. Gallagher, ANP The International AIDS Society–USA DM Gallagher, ANP. Presented at IAS–USA/RWCA Clinical Conference,
Cardiovascular Disease: Predicting Risk and Monitoring Outcomes Monica R. Shah, MD, FACC NHLBI AIDS Coordinator Conference on Retroviruses and Opportunistic.
Are people living with HIV less likely to pass HIV to others if they are on treatment? Exploring the use of treatment as prevention James Wilton Project.
Educational Module Cervical Cancer Screening.  Estimated new cases: 610  Estimated deaths: 150 Regular Pap tests combined with the HPV vaccine can.
What is Diabetes? Diabetes is a chronic disease that occurs either when the pancreas does not produce enough insulin or when the body cannot effectively.
San Francisco HIV Health Services Persons 65 & Older Living with HIV/AIDS in San Francisco: An Introduction Prepared by Robert Whirry, Program Development.
A cost-effectiveness evaluation of preventive interventions for HIV-TB in Sub-Saharan Africa (Tanzania): Relevance for neurological infections Lucie Jean-Gilles.
Creating an AIDS-Free Generation The beginning of the end of AIDS Center for Strategic & International Studies Washington, DC March 22, 2012 Thomas R.
Module 3: HCV prevalence and course of HCV infection.
The Nature of Disease.
Why Healthcare Workers are Key to Ending the AIDS Epidemic Capitol Hill, March 2, 2015 Lisa Carty, Director UNAIDS Liaison Office, Washington, DC 1.
M ALNUTRITION. M ALNUTRITION AMONG IDU S : B ASIC FACTS Drug users are at increased risk of malnutrition regardless of whether or not they are infected.
IAS 2012 feedback: UK Consortium: September 2012 IAS 2012 Feedback: New findings, better drugs and the goal of a cure Simon Collins HIV.
PMTCT Generic Training PackageModule 1Slide 1 Introduction to HIV/AIDS M O D U L E 1.
Clinical Care of HIV, AIDS and Opportunistic Infections
Home Based Care. Presentation Objectives Explain the role of home based care for PLWHAs; Explain the 4 components of home based care; Describe the psychological.
The Strategic Use of ARVs | IAC Satellite, July 22, |1 | Strategic Use of Antiretroviral Drugs WHO Perspective for Future Guidelines Chair of WHO.
Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection DR. S.K CHATURVEDI DR. KANUPRIYA CHATURVEDI.
HIV and STI Department, Health Protection Agency - Colindale HIV and AIDS Reporting System HIV in the United Kingdom: 2012 Overview.
Group 7 Burden of disease in Brazil. KEY HEALTH INDICATORS Years of life lost (YLLs): Years of life lost due to premature mortality. Years lived with.
T-Cell Senescence & Inflammation HIV Research Catalyst Forum, April
I. Jean Davis, PhD, PA, AAHIVS Manager - Clinical Services Desert AIDS Project.
Health Organization The Challenges Facing Tuberculosis Control Blantyre Hospital, Malawi: TB Division, 3 patients per bed.
Surviving Childhood Cancer: What’s Next? Trisha Kinnard PAS 646.
Getting to Zero: Will San Francisco be the first city to succeed? Diane Havlir, MD, Professor of Medicine, UCSF, Chief HIV San Francisco General Hospital.
GERIATRIC TUBERCULOSIS: ISSUES Dr. (Prof.)Vijay Kumar Arora Vice Chancellor Ex Director NITRD Delhi,Ex Director-professor JIPMER, Ex Additional DGHS GOI.
IAS Members Meeting July 19th 2011 Achievements and learning over the past 30 years: what do we need next? Françoise BARRÉ-SINOUSSI Regulation of Retroviral.
HCV Co-infection is Associated with a High Risk of Osteoporotic Fractures Among HIV Patients Roger Bedimo, MD; Henning Drechsler, MD; Song Zhang, PhD;
NHS Cervical Screening Programme Introducing HPV triage and test of cure.
Infectious Diseases STIS. The Chain of Infection Chain of infection: the process by which an infectious agent, or pathogen, passes from one organism to.
The MICRO-HOPE. Microalbuminuria, Cardiovascular and Renal Outcomes in the Heart Outcomes Prevention Evaluation Reference Heart Outcomes Prevention Evaluation.
INDICATORS OF HEALTH STATUS Burden of disease Disability Adjusted Life Year (DALY) Health status Morbidity Life expectancy Prevalence Mortality Incidence.
Acute Renal Failure in HIV- Infected Individuals Greatly Increases Risk for In-Hospital Mortality Slideset on: Wyatt CM, Arons RR, Klotman PE, Klotman.
Linkages between CDs & NCDs: The African context Dr Frank J Mwangemi ICASA 2011: 5 th December 2011 Addis Ababa, Ethiopia.
Problems of HIV Infection in the HAART Era Akihiko Suganuma M.D. Tokyo Metropolitan Komagome Hospital Department of Infectious Diseases.
Provider Initiated HIV Counseling and Testing Unit 1: Introduction to HIV/AIDS.
Slideset on: Emery S, Neuhaus JA, Phillips AN, et al. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving.
NIH HIV/AIDS Research Priorities
Quick Review This presentation is the first in a series of presentations intended to familiarize you with disparities calculation Part I: YOU ARE HERE!
Driving Future Success with Current Investments in HIV Research
3rd International HIV/Viral Hepatitis Co-Infection Meeting HIV/Viral Hepatitis: Improving Diagnosis, Antiviral Therapy and Access Sunday, 17 July.
TREATMENT OF HIV.
WHO strategy on HIV/AIDS “Getting to Zero”
Entry into care Failure to initiate timely HIV care after diagnosis is common ~75% of newly diagnosed link to care within 6-12 months Delayed entry into.
Continuum of HIV Care, Treatment, and Prevention
Non-ARV Based Interventions to Combat HIV/AIDS: New Insights and Initiatives Yves Lévy Inserm, VRI.
HIV in Minnesota: Challenges and Opportunities
Lesson 3: Treatment as Prevention
HUMAN IMMUNODEFICIENCY VIRUS (HIV) PREVENTION & CARE
Presentation transcript:

The Graying of the HIV/AIDS Epidemic in the U.S.

Effects of Aging on the Course of HIV Infection - and Vice Versa - James R. Minor, Pharm.D CAPT, USPHS, Retired jminor101422@gmail.com 919-641-2856 June 2012

Disclaimer

Objectives Describe the clinical issues affecting older HIV+ patients Describe ‘immunosenescence’ and its impact on the course of HIV infection in older patients Summarize HIV-associated, non-AIDS conditions and co-morbidities

HIV/AIDS in Older Persons [50 years of age or older]

Persons 50 years of age+ account for: The Numbers [US] Persons 50 years of age+ account for: 15% of all new HIV infections/year 20% of all new AIDS diagnoses 35% of all deaths due to AIDS 25% of persons living with AIDS [up from 17% in 2001]

Common AIDS and Non-AIDS Complications Organ system Condition / complication AIDS-defining Non-AIDS-defining Cardiovascular Cardiomyopathy √ Myocardial infarction Nervous Toxoplasmosis Primary lymphoma HIV-associated neurocognitive disorder or dementia (HAND or HAD) Pulmonary Tuberculosis (pulmonary or extrapulmonary) Pneumonia (recurrent, or Pneumocystis spp.) Candidiasis (bronchi, trachea, lungs) Renal HIV-associated nephropathy (HIVAN) Bone Reduced bone mineral density Malignancies Invasive cervical cancer (oncogenic HPV) Invasive anal cancer (oncogenic HPV) Non-Hodgkin’s lymphoma, Kaposi’s sarcoma Transition: There are many serious conditions that commonly affect people living with HIV, and not all will result in an AIDS diagnosis, although some certainly can be life-threatening. Main message: Initiation of at higher CD4 counts might help prevent or stall the development of AIDS-defining and perhaps non-AIDS-defining conditions. Background: The incidence of some non-AIDS-defining complications (eg, certain types of malignancies, such as lung cancer or anal cancer; CV disease) has been increasing in recent years as HIV-infected patients live longer. This is one of the reasons that HIV treatment guidelines have shifted towards suggesting that ART be initiated at higher CD4 counts, rather than waiting until the immune system or other organ systems sustain potentially irrevocable damage.

HIV+ persons have a substantially shortened life span, largely due to increased risks of ‘non-AIDS’ complications and comorbid diseases : renal, bone, metabolic, liver, malignant diseases, and neurocognitive decline

Risk of non-AIDS morbidity is higher among ARV-treated HIV+ individuals than in their age-matched, uninfected peers for reasons directly related to the disease or its treatment

All these degenerative comorbid diseases have a negative impact on overall functioning and Quality of Life, and are thought to be related to accelerated or premature aging

‘Immunosenescence’

‘Immunosenescence’ - Definition - Age-related changes in the adaptive immune system that are associated with increased morbidity and mortality “Adaptive” vs. “Innate” immunity

‘Immunosenescence’ Adaptive immune system changes with aging: Decreased number and function of hematopoietic stem cells Thymic dysfunction, involution Decreased circulating naïve T cells Decreased CD4/CD8 ratios Increased proinflammatory cytokines: IL-6, TNFα, CRP, cystatin C Increased pools of senescent CD28- ‘memory’ cells *

Senescent T Cells With aging or in the presence of chronic viral infection, CD28- T cells become resistant to apoptosis and become pro-inflammatory in effector function This contributes to increased systemic inflammation and collateral harm to multiple organ systems Compare apoptosis to auto mechanics

HIV-associated inflammation and ‘immunosenescence’ have been implicated as causally related to the premature onset of multiple end-organ diseases

‘Immunosenescence’ - Summary - HIV-associated immunosenescence contributes to persistent immunodeficiency and early onset of age-related diseases Further investigation into these pathways may lead to novel therapeutic interventions useful in both HIV-infected persons and in uninfected geriatric populations

Prevention and Public Health Challenges in Older HIV+ Persons Many older persons are sexually active but may not be practicing safer sex Older women are at higher risk due to age-related genital changes Many older persons may know less about HIV/AIDS and less likely to protect themselves or to get tested Discrimination and stigma facing older HIV+ may delay testing, diagnosis and entry in treatment

HIV and Aging: Overall Framework

Renal Disease

Renal Disease Untreated HIV disease [persistent viral replication] is associated with higher risks of kidney disease – suggesting that HIV replication directly or indirectly affects the kidneys Many antiretroviral agents [ARVs] are also nephrotoxic

Bone Disease

Bone Disease Prevalence of osteopenia and osteoporosis is at least 3x greater in HIV+ subjects than in HIV uninfected controls Persistent inflammation is probably causally related to bone disease, as many biomarkers of inflammatory bone disease are higher in HIV disease [IL-6, TNF… ] Other contributory factors: ART, vitamin D deficiency

Some factors non-modifiable, others are modifiable

Metabolic and Cardiovascular Complications

HIV, Aging and Increased Risks of Malignant Diseases

Non-AIDS Related Cancers Higher cancer rates in long-term ARV-treated patients is strongly related to the degree of immunodeficiency HIV-associated immune deficiency may be the primary factor driving an excess risk of many non-AIDS cancers Increasing prevalence 0f HCV- and HPV- related malignancies

Covers decade from 1992 to 2003

Kaposi’s Sarcoma

Neurocognitive Functional Defects

HIV-Associated Neurocognitive Disorders [HAND] and Dementia [HAD]: A Hidden Epidemic ??

Neurocognitive Decline HIV-associated inflammation is believed to be a major factor in comorbid CNS disease Debate: Is ongoing CNS disease due to inadequate CNS penetration of ARVs [allowing ongoing viral replication] OR to residual, low-grade inflammation ??

HIV and Aging: Overall Framework

The ‘double insult’ of aging and HIV infection to the hematopoietic system can contribute to many of the factors associated with immunosenescence: chronic inflammation, reduced ability of the immune system to mount effective response to infections, vaccines, other stressors

Novel therapeutic strategies aimed at preventing or reversing immunologic defects and changes related to immunosenescence will be necessary if HIV-infected patients are to achieve normal life spans

COSTS related to the Graying of America – general and in particular HIV/AIDS-related !!!

Advances of modern medicine – people living longer, pursuing active lifestyles, dealing with attendant age-related health issues

Washington Post, circa 1986

Acknowledgements Category Day Organizers, Fellow HCP’s in and out of PHS Uniform, CPO, JO’s, Students and Residents, PATIENTS Category Awardees. Wear uniform with Pride and Distinction, Speak, Publish !!

The Graying of the HIV/AIDS Epidemic in the U. S. jminor101422@gmail The Graying of the HIV/AIDS Epidemic in the U.S. jminor101422@gmail.com

Linkage to Care - US and EU There are still a significant number of patients who are undiagnosed, not linked into care and not on therapy

Keys to Achieving Long-Term Objective of Ending the HIV/AIDS Pandemic * Efficiently identify greater numbers of HIV+ people earlier in the course of disease through expanded voluntary HIV testing programs, and link them to appropriate care and antiretroviral treatment Find innovative approaches to curing HIV/AIDS by eradicating or permanently suppressing the virus in infected people, thereby eliminating the need for lifelong antiretroviral therapy Scale-up implementation of proven HIV prevention strategies, develop additional effective prevention strategies, such as a vaccine, and build on current successes in pre-exposure prophylaxis, microbicides and ‘treatment-as-prevention’ to achieve a sustainable and comprehensive, combination HIV prevention strategy * NIH/NIAID, 31 May 2011

“HIV testing should be the fifth vital sign” Carl Dieffenbach, Director, DAIDS, NIAID 1 June 2011

HIV Prevention – Recent Milestones - Two populations are disproportionately affected by HIV Men who have sex with men (MSMs) Women - nearly half of the adults living with HIV. CAPRISA-004: 39% reduction in new HIV infections in women with the use of topical 1% Tenofovir gel; first trial to prove efficacy of PrEP iPrEx: 44% reduction in new infections when TDF/FTC was used daily as pre-exposure prophylaxis (PrEP) in MSMs